vasculature, frequent expression of CD34, and negativity for epithelial membrane antigen (EMA). 11 No clinical or radiological features accurately distinguish SFT from HPC, and in some cases, it is difficult to discriminate SFT from HPC even based on histological and immunohistochemical features.
2 Nonetheless, intracranial SFT and HPC were declared separate entities with different prognoses. 15, 24, 30 Recently, whole-exome sequencing revealed a unique NAB2-STAT6 fusion in SFTs. 6 A validation study on meningeal tumors showed that the same fusion occurred in SFT and HPC and suggested combining intracranial SFT and HPC into a single disease entity. 36 For this reason, the 2016 WHO classification of central nervous system (CNS) tumors included the combined term "SFT/HPC" to describe such lesions, and 3 grades were assigned to the entity of SFT/HPC. 25 The changes in the pathological classification may represent the different clinical prognoses and the requirement for different treatment strategies. Although most studies have recommended a multimodal treatment strategy, very little of the published literature has reported long-term follow-ups, and only a few studies have suggested that the 2016 WHO classification reflects patient prognosis better than prior pathological classifications. When considering observation or additional treatment after surgery for intracranial SFT/HPC, it is important to understand the clinical outcomes of this entity in order to improve patient outcomes. The purpose of the present study was to investigate the clinicopathological factors of intracranial SFT/HPC that affect clinical progression and patient survival and to suggest an appropriate treatment strategy based on the 2016 WHO classification. Here, we analyzed the clinical outcomes of 47 patients with SFT/HPC when considering the changes in classification.
Methods
This study was approved by the institutional review board at our institute and is in accordance with the Declaration of Helsinki. We collected from the pathology database at our hospital those cases that had been histologically diagnosed as intracranial SFT, HPC, and anaplastic HPC. Medical and radiological records for the patients were retrospectively reviewed. All patients had initially undergone resection. Two neuropathologists performed the pathological review. Information on age, sex, tumor location, tumor size, extent of resection, pathology, adjuvant radiotherapy, tumor recurrence or metastasis, and patient survival was collected. Tumor size was obtained by measuring the maximal diameter on the preoperative MR images. The neuroimaging evaluation of all patients had been conducted preoperatively as well as within 3 months of surgery. The extent of resection was classified as grosstotal resection (GTR) or subtotal resection (STR) based on the postoperative MRI study. Gross-total resection was defined as Simpson grade I or II removal, whereas STR was defined as Simpson grade III removal. Adjuvant radiotherapy, such as external beam radiation therapy (EBRT) or Gamma Knife surgery (GKS), was suggested for tumors that manifested malignant pathological features or that were not treated with GTR. Progression was defined as the reappearance of tumor within the cranial cavity or an increase in the size of residual tumor. Metastasis was defined as the presence of HPC tissue in extracranial locations.
Pathology
The typical SFT shows a patternless architecture characterized by a combination of alternating hypocellular and hypercellular areas separated from each other by thick bands of hyalinized, sometimes keloidal or amianthoidlike collagen and thin-walled staghorn vessels. The typical HPC is characterized by highly cellular, less collagenous tumors with plump cells and thin-walled, branching HPClike (staghorn) vessels. In a 3-tiered system, classic SFT was histologically considered benign at grade I, whereas HPC was considered malignant. Hemangiopericytomas were subclassified as grade II or grade III (anaplastic) depending on the mitotic count (< 5 vs ≥ 5 mitoses per 10 hpf) and/or necrosis plus at least 2 of the following: hemorrhage, moderate to high nuclear atypia, or cellularity. 24, 28 All specimens were regraded by the 2 neuropathologists (Y.K. and Y.L.S.) according to the 2016 WHO classification. There was no disagreement on the pathological diagnosis between the 2 neuropathologists. They doublechecked the diagnoses of the included cases. At the time of diagnosis, cases that had been hard to differentiate from meningioma had a differential diagnosis via reticulin and immunohistochemical staining using EMA, claudin-1, claudin-11, CD34, Bcl-2, CD99, and electron microscopy study. Meningioma was reactive to at least 1 of 3 markers (EMA, claudin-1, or claudin-11). In cases with overlapping histopathological and immunohistochemical features of meningioma and SFT/HPC, meningioma could be excluded based on diagnostic ultrastructural features, such as complex interdigitating cellular processes and desmosomal intercellular junctions. The 2016 WHO classification assigns 3 grades within the entity of SFT/HPC: 25 grade I is defined as the tumors previously diagnosed as SFT (Fig. 1A) ; grade II, as the tumors previously diagnosed as HPC in the CNS (Fig. 1B) ; and grade III, as the tumors previously diagnosed as anaplastic HPC on the basis of ≥ 5 mitoses per 10 hpf (Fig. 1C) . Solitary fibrous tumor with malignant features such as high mitotic activity (≥ 5 mitoses per 10 hpf) was assigned a WHO grade III. A comparison between old and new WHO classifications is featured in Table 1 . According to the original diagnoses in the chart review, 10 patients had SFT, 33 had HPC, and 4 had anaplastic HPC. Twenty-two cases diagnosed as HPC before 2007 had not been graded, 11 of which were reclassified as HPC grade III based on the 2016 WHO classification of CNS tumors.
Statistical Analysis
Progression-free survival (PFS) was calculated as the time from the date of initial surgery following a pathological diagnosis of SFT or HPC to the date of documented tumor recurrence or further growth of residual tumor. Overall survival (OS) was calculated as the time from the initial surgery to death or the last-known date of posttreatment follow-up. Analyses for progression and survival were based on the primary intervention that a patient received. The factors associated with PFS and OS were statistically evaluated with uni-and multivariate analyses. Univariate survival analysis was performed using the Kaplan-Meier method to evaluate prognostic factors. Significance was determined using the log-rank test, with a p value considered significant at the 5% level (that is, p < 0.05). A multivariate Cox regression analysis was then performed to determine the independent impact of factors found to be significant in the univariate analysis.
All statistical analyses were performed using IBM SPSS Statistics 23.0 (IBM Corp.).
Results

Patient Characteristics
Forty-seven patients with primary intracranial SFT or HPC were treated in our department in the period from June 1996 to September 2014 (Table 2 ). There were 30 male (63.8%) and 17 female (36.2%) patients, with a median age of 38 years (range 22-77 years) at initial diagnosis. Thirty-nine tumors (83.0%) were in supratentorial locations and 8 (17.0%) in infratentorial locations. The mean and median follow-up periods were 114.6 and 94.7 months, respectively (range 7.1-366.7 months). At the first visit, the median maximal tumor diameter measured on brain MR images was 6.0 cm (range 2.3-9.0 cm). Twenty-three patients (48.9%) had undergone preoperative embolization. Ten patients (21.3%) had died by the time of the retrospective analysis. The mean survival time across all patients was 246.7 months (95% CI 188.1-305.4 months) after the date of diagnosis, with 1-, 5-, and 10-year survival rates of 97.8%, 92.7%, and 69.5%, respectively. Twenty-seven patients (57.4%) experienced at least 1 progression or recurrence. The mean time to progression or recurrence was 102.0 months (95% CI 74.4-129.6 months) after the date of diagnosis, with 1-, 5-, and 10-year PFS rates of 87.1%, 56.0%, and 34.6%, respectively. Ten patients (21.3%) developed extracranial metastases. The mean time to the development of extracranial metastases was 226.8 months (95% CI 168.3-285.4 months). The extracranial metastasis-free survival rates at 1, 5, and 10 years were 97.4%, 94.5%, and 81.1%, respectively. The sites of extracranial metastases were the liver (7 patients), bones (7 patients), lung (5 patients), spine (5 patients), and kidney (2 patients).
Univariate and Multivariate Analyses of Factors Related to PFS and OS
We evaluated the effect of prognostic values on PFS and OS for variables such as age, sex, tumor size, tumor location, extent of resection, adjuvant radiation, and pathology. Univariate analyses showed that the extent of resection and adjuvant radiation were significantly associated with tumor recurrence (p < 0.05), whereas age, sex, tumor location, tumor size, and pathology were not. Both GTR and adjuvant radiation, as compared with STR and the absence of adjuvant radiation, were significantly associated with longer PFS (p < 0.05). Age, sex, and extent of resection were also positively correlated with OS (p < 0.05). An age over 60 years, male sex, and GTR were associated with significantly better OS (p < 0.05) than were an age under 60 years, female sex, and STR. The factors of sex, extent of resection, adjuvant radiation, and pathology were included in the Cox regression analyses. (Because some of the literature has reported pathology as a significant prognostic factor and given the possibility of selection bias, we included pathology in our regression analysis.) The results revealed that GTR remained significantly and positively correlated with PFS and OS (p < 0.05). Adjuvant radiation was significantly positively correlated with PFS (p = 0.033; Table 3 ).
Pathology
Applying the 2016 WHO classification, we reclassified conventional SFT as WHO grade III SFT/HPC in 2 cases (Fig. 2) , and 13 original HPC cases were relabeled as WHO grade III SFT/HPC (Fig. 3) The grade III SFT/HPC group that had been regraded from conventional SFT or HPC showed higher recurrence rates, more frequent extracranial metastases, and higher mortality rates (Table 4) 
Extent of Resection
Gross-total resection was achieved in 33 patients (70.2%) and STR in 14 patients (29.8%). After GTR, 13 (39.4%) of 33 patients received adjuvant EBRT and 1 (3.0%) of 33 underwent GKS. Five patients (35.7%) who had undergone STR were further treated with adjuvant radiation, including 4 (28.6%) who received EBRT and 1 (7.1%) who underwent GKS. Three patients (9.1%) who had undergone GTR and 7 (50.0%) who had undergone STR had died by the time of our analysis ( Fig. 5B ).
Multidisciplinary Approach Combining Radical Resection With Adjuvant Radiation Therapy
Patients undergoing any form of adjuvant radiation treatment, including EBRT and GKS, had longer mean PFS than those who did not undergo such treatment (126.9 vs 74.8 months, p = 0.018; Fig. 6C ). When considering the extent of resection, patients who had undergone GTR alone demonstrated significantly superior OS than those who had undergone STR with or without adjuvant radiation (327.5 vs 151.4 months, p = 0.048; Fig. 6D ). Patients who had undergone GTR with adjuvant radiation showed a trend toward an increased time to recurrence as compared with those who had undergone GTR alone (p = 0.076). We found no significant difference in the time to recurrence between the patients treated with GTR alone and those treated using STR with or without adjuvant radiation (p = 0.261), between patients treated with GTR alone and those treated with STR plus adjuvant radiation (p = 0.954), or between patients treated with STR plus adjuvant radiation and those treated with STR alone (p = 0.422). Patients who had undergone any form of adjuvant radiation treatment with resection demonstrated worse OS than those who had undergone surgery alone, but the difference was not statistically significant (196.1 vs 257.8 months, respectively, p = 0.977). In an analysis of the extent of resection, there was a statistical trend toward better OS among the patients who had undergone GTR alone versus those who had undergone STR with adjuvant radiation (332.4 vs 112.2 months, p = 0.076). We found no significant difference in OS between patients treated with GTR plus adjuvant radiation and those treated with GTR alone (p = 0.562) or between patients treated with STR plus adjuvant radiation and those treated with STR alone (p = 0.854). Extracranial metastasis in patients treated using STR with or without adjuvant radiation was more common in those with grade III SFT/HPC than in those with grade II SFT/HPC (62.5% vs 16.7%).
Discussion
Intracranial SFT is generally benign since GTR can be achieved and only 14% of gross-totally resected SFT cases recur. 12 In contrast, HPC is considered malignant because of its tendency to recur and develop extracranial metastases despite GTR. 10, 33, 40, 42 Hemangiopericytoma was subclassified into 2 histological subtypes depending on the mitotic count; that is, HPC was considered a WHO grade II tumor, and anaplastic HPC was considered a grade III tumor. 24, 28 Anaplastic HPC with WHO grade III was defined as the presence of high mitotic activity of more than 5 mitoses per 10 hpf and/or necrosis plus at least 2 of the following: hemorrhage, moderate to high nuclear atypia, or cellularity. Hence, adjuvant radiotherapy for patients diagnosed with grade II or III HPC is beneficial for eliminating the risk of recurrence. 13, 14 In the 2013 WHO classification of soft tissue and bone, 19 the term "HPC" was omitted, leaving the single unified entity of SFT subdivided into levels of malignancy. The 2016 WHO classification of CNS tumors combined intracranial SFT and HPC into a single disease entity because of the discovery of NAB2-STAT6 fusion using whole-exome sequencing.
In our study, median age at the time of diagnosis was 38 years, and males were affected more frequently than females, similar to reports by other investigators. 8, 28, 35 When we evaluated prognostic factors associated with PFS and OS by using uni-and multivariate analyses, GTR was an important factor correlated with PFS and OS, and adjuvant radiation therapy was significantly associated with PFS.
Currently, the association of pathological grade with recurrence and survival is controversial. Very few authors have analyzed pathology-related PFS and OS according to the 2016 WHO classification of CNS tumors. Bouvier et al.
2 classified SFT and HPC into Marseille grades I, IIa, IIb, and III. They reported that the grade of tumor malignancy negatively correlated with patient PFS and OS in the SFT/HPC group. In our study, grading the SFT/ HPC according to the 2016 WHO classification revealed no significant association with PFS and OS (p > 0.05). However, grade III SFT/HPC cases regraded from conventional SFT or HPC showed higher recurrence rates, more frequent extracranial metastases, and higher mortality rates. These results show that the 2016 WHO classification reflects the malignant pathological potential better than prior pathological classifications. Several studies analyzing the clinical outcome of HPC have reported that high-grade tumors have higher recurrence rates than lowgrade tumors. 10, 28, 35 Moreover, Damodaran et al. 8 demon- strated that high-grade tumors were correlated with worse survival rates than low-grade tumors, but there was no significant association between pathological grade and recurrence. Our study showed that grade I SFT/HPC with the classic SFT phenotype led to significantly superior PFS than grade II and III SFT/HPC with an HPC phenotype (146. Many studies investigating either SFT or HPC have similarly concluded that GTR is an important prognostic factor for survival and recurrence. 4, 5, 27, 31 Gross-total resection rates reportedly vary from 20.9% to 85%. 5 reviewed the clinical outcomes of 38 patients with HPC with a mean follow-up of 61 months. In their study, GTR was achieved in 83% of the cases and the average OS time in the GTR group was significantly higher than that in the STR group (120 vs 68 months, p = 0.013). The mean PFS time in the GTR group was significantly higher than that in the STR group (100 vs 50 months, p = 0.006). Melone et al. 27 described their experience with 43 cases over a median follow-up of 118 months. Gross-total resection was achieved in 70% of the cases. These authors reported that OS and PFS of the patients treated with GTR were significantly longer than those of the patients treated with STR (p = 0.047 and 0.0025, respectively). Meanwhile, Ghia et al.
14 analyzed 63 patients diagnosed with meningeal HPC and reported a GTR rate of 49%; in addition, GTR was an independent predictor of improved PFS (p = 0.008) but not of OS (p = 0.54). In our study, the GTR group demonstrated longer OS and PFS than those in the STR group (p < 0.05), corroborating most other studies. A multidisciplinary approach combining radical resection with adjuvant radiation therapy in any form, including EBRT, stereotactic radiosurgery, and proton beam radiotherapy, was applied in an earlier study; 1 this strategy was used given concerns regarding metastatic potential and infiltration into nerves, vessels, and neurocritical structures surrounding tumors. Results from analyses of the extent of resection indicated that patients undergoing GTR showed better OS than those undergoing STR with any form of adjuvant radiation. 27, 33, 34 In Rutkowski et al.'s review, as in our own study, the patients undergoing GTR alone showed improved OS compared with that in patients undergoing STR with or without adjuvant radiation. 34 However, Ghia et al. reported that patients who had undergone STR with postoperative EBRT compared favorably in terms of OS with those who had undergone GTR alone.
14 Therefore, GTR preserving neurological function should be the primary treatment goal for patients with SFT/HPC. Currently, postoperative adjuvant radiation shows contradictory results for survival. Several authors have reported that the use of postoperative adjuvant radiation combined with surgery decreases recurrence rates with no survival benefit, 27,33 whereas others have reported improved survival and decreased recurrence rates. 9, 16, 35, 37, 38 Our results showed that the addition of adjuvant radiation regardless of the extent of resection did not significantly improve survival but did reduce recurrence rates (p = 0.018). In the literature, a focal fractionated radiotherapy dose of 50 Gy is recommended as a standard to prevent recurrence. 9, 13, 16, 23 However, there is no current standard protocol regarding the optimal modality or dose of radiotherapy. There are also few publications in the literature reporting the effects of radiotherapy on SFT.
26,32 However, we found that there was a significant correlation between adjuvant radiation therapy and PFS in the SFT/HPC group. Therefore, adjuvant radiation therapy can be administered in patients with SFT/HPC that shows malignant features or that has not been completely resected.
The reported incidence of extracranial metastases ranges from 12.0% to 55.0%. 5, 9, 21, 27, 33, 35, 37, 39, 40 The most common sites of metastasis are the liver, lung, bone, abdominal cavity, kidney, and pancreas. The average time to the development of extracranial metastases is controversial, but the reported interval from the primary operation to the first extracranial metastases has ranged from 8 to 16 years. 22 Our study showed similar results for incidence, metastasis sites, and interval to the development of extracranial metastases. Kim et al. reported that extracranial metastases appeared to be more common in high-grade HPC and that the development of extracranial metastases leads to a significant reduction in survival time, with an average of 24 months after the identification of extracranial metastases.
20 Table 6 summarizes the clinical outcomes in prior studies of SFT and HPC that used either the new or the old grading system. In our assessment, grade III SFT/HPC was strongly correlated with the development of extracranial metastases. Eight of the 10 patients who had died had grade III SFT/HPC, 5 of them had extracranial metastases, and extracranial metastases were confirmed as the direct cause of death in 3 patients. Earlier studies have reported that GTR may favorably affect the development of extracranial metastases, 29, 43 and our data demonstrated that patients treated with GTR had a significantly longer extracranial metastasis-free interval than the patients treated with STR (270.2 vs 149.4 months). Therefore, long-term surveillance for extracranial metastasis is needed to prolong survival among patients who have undergone GTR.
Conclusions
The 2016 WHO classification of CNS tumors reflects the prognosis for PFS and OS better than prior classifications by unifying 2 disease entities into the single term "SFT/HPC" and by reflecting the different types of malignant pathological progression. Grades II and III SFT/HPC are associated with a reduced time to progression, whereas grade III SFT/HPC is significantly correlated with higher recurrence rates, more frequent extracranial metastases, and higher mortality rates. Gross-total resection preserving neurological function should be the primary treatment goal for SFT/HPC. Radiation can be administered as adjuvant therapy for cases of SFT/HPC that show an aggressive phenotype or that are not treated with GTR. Extracranial metastasis is a common cause of death, particularly in grade III SFT/HPC; therefore, long-term close surveillance is recommended.
